TLRY Tilray Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TLRY

Price (delayed)

$3.88

Market cap

$452.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$14.65

Enterprise value

$519.78M

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 5
Relative Valuation: Rel. Valuation: 36
Relative Profitability: Rel. Profitability: 8

Tilray is a Canadian pharmaceutical and cannabis company, incorporated in the United States with primary operations headquartered in Toronto, Ontario. Tilray also has operations in Australia, New Zealand, Germany, Portugal, ...

Highlights
The debt has contracted by 8% YoY
TLRY's revenue is up by 3.8% year-on-year and by 2.5% since the previous quarter
TLRY's net income is down by 41% YoY but it is up by 36% from the previous quarter
The EPS is down by 40% year-on-year but it is up by 37% since the previous quarter
TLRY's equity is down by 43% year-on-year
Tilray's gross margin has decreased by 10% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: https://www.tilray.com/
Peers: OPK ORGO

Key stats

What are the main financial stats of TLRY

TLRY stock price

How has the Tilray stock price performed over time
Intraday
-2.76%
1 week
-9.77%
1 month
-15.47%
1 year
-44.81%
YTD
-57.03%
QTD
-13.59%

Financial performance

How have Tilray's revenue and profit performed over time
Revenue
$858.28M
Gross profit
$237.55M
Operating income
-$1.51B
Net income
-$1.35B
Gross margin
27.7%
Net margin
-156.7%
The operating income has dropped by 76% year-on-year but it has increased by 33% since the previous quarter
The operating margin has plunged by 70% YoY but it has grown by 34% from the previous quarter
TLRY's net income is down by 41% YoY but it is up by 36% from the previous quarter
The net margin has grown by 38% from the previous quarter but it has contracted by 36% YoY

Price vs fundamentals

How does TLRY's price correlate with its fundamentals

Growth

What is Tilray's growth rate over time

Valuation

What is Tilray stock price valuation
P/E
N/A
P/B
0.29
P/S
0.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.61
The EPS is down by 40% year-on-year but it is up by 37% since the previous quarter
The price to book (P/B) is 52% lower than the 5-year quarterly average of 0.6 and 52% lower than the last 4 quarters average of 0.6
TLRY's equity is down by 43% year-on-year
TLRY's price to sales (P/S) is 82% less than its 5-year quarterly average of 2.9 and 54% less than its last 4 quarters average of 1.1
TLRY's revenue is up by 3.8% year-on-year and by 2.5% since the previous quarter

Efficiency

How efficient is Tilray business performance
The company's return on equity has shrunk by 200% YoY but it rose by 24% QoQ
The company's return on assets has shrunk by 173% YoY but it rose by 26% QoQ
The ROIC has plunged by 64% YoY but it has grown by 34% from the previous quarter
The ROS is down by 48% year-on-year but it is up by 36% since the previous quarter

Dividends

What is TLRY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TLRY.

Financial health

How did Tilray financials performed over time
Tilray's total assets has decreased by 39% YoY
The total liabilities has contracted by 22% YoY
The debt is 80% less than the equity
Tilray's debt to equity has surged by 54% YoY
TLRY's equity is down by 43% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.